These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 25211626)

  • 1. 18F-FDG PET-CT scanning and diabetic patients: what to do?
    Martin J; Saleem N
    Nucl Med Commun; 2014 Dec; 35(12):1197-203. PubMed ID: 25211626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do hyperglycemia and diabetes affect the incidence of false-negative 18F-FDG PET/CT studies in patients evaluated for infection or inflammation and cancer? A Comparative analysis.
    Rabkin Z; Israel O; Keidar Z
    J Nucl Med; 2010 Jul; 51(7):1015-20. PubMed ID: 20554733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does hyperglycemia affect the diagnostic value of 18F-FDG PET/CT?
    Mirpour S; Meteesatien P; Khandani AH
    Rev Esp Med Nucl Imagen Mol; 2012; 31(2):71-7. PubMed ID: 22088805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrashort-acting insulin may improve on 18F-FDG PET/CT image quality in patients with uncontrolled diabetic mellitus.
    Song HS; Yoon JK; Lee SJ; Yoon SH; Jo KS; An YS
    Nucl Med Commun; 2013 Jun; 34(6):527-32. PubMed ID: 23511925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of subcutaneous administration of rapid-acting insulin in the quality of (18)F-FDG PET/CT studies.
    Garcia JR; Sanchis A; Juan J; Tomas J; Domenech A; Soler M; Moragas M; Riera E
    Nucl Med Commun; 2014 May; 35(5):459-65. PubMed ID: 24535382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDGPET/CT: diabetes and hyperglycaemia.
    Niccoli-Asabella A; Iuele FI; Merenda N; Pisani AR; Notaristefano A; Rubini G
    Nucl Med Rev Cent East Eur; 2013; 16(2):57-61. PubMed ID: 24068633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is (18)F-FDG-PET/CT prognostic factor for survival in patients with small cell lung cancer? Single center experience.
    Inal A; Kucukoner M; Kaplan MA; Urakci Z; Nas N; Guven M; Dostbil Z; Altindag S; Isikdogan A
    Rev Port Pneumol; 2013; 19(6):260-5. PubMed ID: 23993406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
    Abe Y; Tamura K; Sakata I; Ishida J; Ozeki Y; Tamura A; Uematsu K; Sakai H; Goya T; Kanazawa M; Machida K
    Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant disease as an incidental finding at ¹⁸F-FDG-PET/CT scanning in patients with granulomatous lung disease.
    Huber H; Hodolic M; Stelzmüller I; Wunn R; Hatzl M; Fellner F; Lamprecht B; Rubello D; Colletti PM; Gabriel M
    Nucl Med Commun; 2015 May; 36(5):430-7. PubMed ID: 25646704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of soft-tissue lesions with (18)F-FDG PET/CT: initial results of a prospective trial.
    Leal AL; Etchebehere M; Santos AO; Kalaf G; Pacheco EB; Amstalden EM; Etchebehere EC
    Nucl Med Commun; 2014 Mar; 35(3):252-9. PubMed ID: 24300379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low positive yield from routine inclusion of the brain in whole-body 18F-FDG PET/CT imaging for noncerebral malignancies: results from a large population study.
    Manohar K; Bhattacharya A; Mittal BR
    Nucl Med Commun; 2013 Jun; 34(6):540-3. PubMed ID: 23503001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results.
    Ozkan E; Aras G; Kucuk NO
    Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Semiquantitative Analysis of the Biodistribution of the Combined ¹⁸F-NaF and ¹⁸F-FDG Administration for PET/CT Imaging.
    Minamimoto R; Mosci C; Jamali M; Barkhodari A; Habte F; Jackson T; Mittra E; Gambhir SS; Iagaru A
    J Nucl Med; 2015 May; 56(5):688-94. PubMed ID: 25840978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does 18F-FDG PET/MRI reduce the number of indeterminate abdominal incidentalomas compared with 18F-FDG PET/CT?
    Schaarschmidt BM; Grueneisen J; Heusch P; Gomez B; Umutlu L; Ruhlmann V; Rosenbaum-Krumme S; Antoch G; Buchbender C
    Nucl Med Commun; 2015 Jun; 36(6):588-95. PubMed ID: 25759944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incremental value of 18F-FDG PET/CT in therapeutic decision-making of potentially curable esophageal adenocarcinoma.
    Purandare NC; Pramesh CS; Karimundackal G; Jiwnani S; Agrawal A; Shah S; Kulkarni M; Laskar SG; Rangarajan V
    Nucl Med Commun; 2014 Aug; 35(8):864-9. PubMed ID: 24751701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between positive thyroglobulin doubling time and 18F-FDG PET/CT-positive, 131I-negative lesions.
    Kelders A; Kennes LN; Krohn T; Behrendt FF; Mottaghy FM; Verburg FA
    Nucl Med Commun; 2014 Feb; 35(2):176-81. PubMed ID: 24201550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
    Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
    Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association between diabetes mellitus and reduction in myocardial glucose uptake: a population-based
    Hu L; Qiu C; Wang X; Xu M; Shao X; Wang Y
    BMC Cardiovasc Disord; 2018 Oct; 18(1):203. PubMed ID: 30373519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.